Vima LLC’s ARK Genomic Revolution ETF ARKG Stock Holding History

Vima LLC’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-103	Closed	-$2.96K	–	89
2024 Q1	$2.96K	Sell	103 -19	-16%	-$571	﹤0.01%	322
2023 Q4	$4K	Buy	+122	New	+$3.32K	0.01%	308

Other funds holding ARKG

MMEA

Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Vima LLC's ARKG Position: Q2 2024 in Review

Vima LLC sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2024, closing a stake of 103 shares — an estimated $2.96K sold.

Vima LLC first reported a position in ARKG in Q4 2023 and held it in 2 quarters. The position peaked at $4K in Q4 2023. 262 funds tracked by Wall St. Rank hold ARKG as of Q2 2024.

Vima LLC reported no remaining ARK Genomic Revolution ETF position as of Q2 2024 after selling out during the quarter.
Vima LLC sold 103 ARK Genomic Revolution ETF shares in Q2 2024, an estimated $2.96K.
Vima LLC first reported a position in ARK Genomic Revolution ETF in Q4 2023 and held it in 2 quarters.
Vima LLC's ARK Genomic Revolution ETF position peaked at $4K in Q4 2023.
262 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2024.

Based on Vima LLC's 13F filing for Q2 2024, filed 8 Aug 2024.